Ipca Laboratories Ltd. informed
the exchanges that it has entered an agreement with a leading product
development partnership, Medicines for Malaria Venture (MMV), to
co-develop a novel antimalarial co-formulation named "Atoguanil".
Atoguanil, based on proprietary Ipca technology, contains the active pharmaceutical ingredients atovaquone and proguanil. Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries. Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis.
Ipca Laboratories Ltd is currently trading at Rs1,133.50 down by Rs5.3 or 0.47% from its previous closing of Rs1,138.80 on the BSE.
The scrip opened at Rs1,141 and has touched a high and low of Rs1,143.40 and Rs1,130 respectively. So far 1,03,446 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs14,388.98cr.
Atoguanil, based on proprietary Ipca technology, contains the active pharmaceutical ingredients atovaquone and proguanil. Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries. Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis.
Ipca Laboratories Ltd is currently trading at Rs1,133.50 down by Rs5.3 or 0.47% from its previous closing of Rs1,138.80 on the BSE.
The scrip opened at Rs1,141 and has touched a high and low of Rs1,143.40 and Rs1,130 respectively. So far 1,03,446 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs14,388.98cr.
0 comments:
Post a Comment
Please add comment